Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

We did not find any statistically significant differences in the intake of calcium, fiber, vitamin D, vitamin B12, magnesium, zinc, or saturated fatty acids (data not shown).

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Open-label reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A randomized clinical trial was conducted to evaluate the impact of a gluten-free diet (GFD) on β-cell function and glucose tolerance in persons with multiple islet autoantibodies.

Source: Abstract.

The participants were randomized to a GFD (n = 30; female n = 14) or a normal diet (ND) (n = 29; female n = 16).

Source: Abstract.

In this open-label randomized controlled clinical trial, 59 participants were enrolled to follow either a GFD or ND (control group).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

β-Cell Function and Glucose Tolerance in Persons With Multiple Islet Autoantibodies Randomized to a Gluten-free Diet

Randomised controlled trial · Journal of the Endocrine Society · 2025

Original publication title

β-Cell Function and Glucose Tolerance in Persons With Multiple Islet Autoantibodies Randomized to a Gluten-free Diet

Marlena Maziarz; Jaakko J Koskenniemi; Maria Månsson Martinez; Lampros Spiliopoulos; Falastin Salami; Jorma Toppari; Jukka Kero; Riitta Veijola; Päivi Tossavainen; Sauli Palmu; Carin Andrén Aronsson; Markus Lundgren; Henrik Borg; Anastasia Katsarou; Helena Elding Larsson; Mikael Knip; Olivia Lou; Jessica L Dunne; Carina Törn; Åke Lernmark

© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Being on a GFD was not found to differ from being on a ND in preserving β-cell function or maintaining normal glucose tolerance in persons with multiple islet autoantibodies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

A randomized clinical trial was conducted to evaluate the impact of a gluten-free diet (GFD) on β-cell function and glucose tolerance in persons with multiple islet autoantibodies.

Source: Purpose

Abstract: What methods does the paper describe?

Individuals (n = 59; median age 11 years) with multiple islet autoantibodies were recruited to a randomized clinical trial between April 2016 and April 2021. The participants were randomized to a GFD (n = 30; female n = 14) or a normal diet (ND) (n = 29; female n = 16). The study was conducted at 6 clinical research centers in Finland and Sweden, with a dietary intervention for 17 months followed by a 6-month washout on a ND. The primary outcomes were (1) the proportion of participants going from normal glucose tolerance at the time of the randomization to abnormal glucose tolerance by 18 months, (2) a change in first-phase insulin response in IV glucose tolerance tests between randomization and 18 months, and (3) a change in C-peptide area under the curve in oral glucose tolerance test between randomization and 18 months.

Source: Methods

Abstract: Results

We did not find differences between participants randomized to GFD and ND in any of the glucose tolerance outcomes. No serious adverse events or adverse events related to a GFD were noted.

Source: Results

Abstract: Conclusion

Being on a GFD was not found to differ from being on a ND in preserving β-cell function or maintaining normal glucose tolerance in persons with multiple islet autoantibodies.

Source: Conclusion
Authors’ abstract

Abstract

Purpose

A randomized clinical trial was conducted to evaluate the impact of a gluten-free diet (GFD) on β-cell function and glucose tolerance in persons with multiple islet autoantibodies.

Methods

Individuals (n = 59; median age 11 years) with multiple islet autoantibodies were recruited to a randomized clinical trial between April 2016 and April 2021. The participants were randomized to a GFD (n = 30; female n = 14) or a normal diet (ND) (n = 29; female n = 16). The study was conducted at 6 clinical research centers in Finland and Sweden, with a dietary intervention for 17 months followed by a 6-month washout on a ND. The primary outcomes were (1) the proportion of participants going from normal glucose tolerance at the time of the randomization to abnormal glucose tolerance by 18 months, (2) a change in first-phase insulin response in IV glucose tolerance tests between randomization and 18 months, and (3) a change in C-peptide area under the curve in oral glucose tolerance test between randomization and 18 months.

Results

We did not find differences between participants randomized to GFD and ND in any of the glucose tolerance outcomes. No serious adverse events or adverse events related to a GFD were noted.

Conclusion

Being on a GFD was not found to differ from being on a ND in preserving β-cell function or maintaining normal glucose tolerance in persons with multiple islet autoantibodies.

Publication and source details

Original title: β-Cell Function and Glucose Tolerance in Persons With Multiple Islet Autoantibodies Randomized to a Gluten-free Diet

Marlena Maziarz; Jaakko J Koskenniemi; Maria Månsson Martinez; Lampros Spiliopoulos; Falastin Salami; Jorma Toppari; Jukka Kero; Riitta Veijola; Päivi Tossavainen; Sauli Palmu; Carin Andrén Aronsson; Markus Lundgren; Henrik Borg; Anastasia Katsarou; Helena Elding Larsson; Mikael Knip; Olivia Lou; Jessica L Dunne; Carina Törn; Åke Lernmark

Journal of the Endocrine Society · 2025

Correspondence: Åke Lernmark, PhD, Department of Clinical Sciences, Lund University CRC, Jan Waldenströms gata 35, Skåne University Hospital, Malmö 214 28, Sweden. Email: ake.lernmark@med.lu.se.

Marlena Maziarz and Jaakko J Koskenniemi shared first authorship.

Jaakko J Koskenniemi: Current address is Health Informatics Institute, Morsani College of Medicine, University of South Florida, 3650 Spectrum Blvd, Suite 100, Tampa, FL 33612, USA.

© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms. JDRF International10.13039/100022690 2-SRA-2014-309-M-R Swedish Foundation Dnr IRC15-0067 Swedish Research Council10.13039/501100004359 Dnr 2009-1039 University Hospitals in Finland

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T05:17:21.186072+00:00

DOI: 10.1210/jendso/bvaf073 · PMC12146266